Orladeyo Capsule
NDC Package 72769-101-01
Package Information
Orladeyo (berotralstat hydrochloride) capsules is oRLADEYO™ is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older. This formulation utilizes a capsule delivery system. Marketed by Biocryst Pharmaceuticals, Inc., this product is identified by NDC 72769-101 and is authorized under FDA application NDA214094.
Identification & Billing
- RxCUI: 2467565 - berotralstat 150 MG Oral Capsule
- RxCUI: 2467571 - orladeyo 150 MG Oral Capsule
- RxCUI: 2467571 - berotralstat 150 MG Oral Capsule [Orladeyo]
- RxCUI: 2467571 - Orladeyo 150 MG Oral Capsule
- RxCUI: 2467573 - berotralstat 110 MG Oral Capsule
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 72769 - Biocryst Pharmaceuticals, Inc.
- 72769-101 - Orladeyo
- 72769-101-01 - 4 DOSE PACK in 1 CARTON / 1 BLISTER PACK in 1 DOSE PACK / 7 CAPSULE in 1 BLISTER PACK
- 72769-101 - Orladeyo
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 72769-101-01 identifies a specific commercial package of 4 dose pack in 1 carton / 1 blister pack in 1 dose pack / 7 capsule in 1 blister pack of Orladeyo, a human prescription drug labeled by Biocryst Pharmaceuticals, Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 4 billable units per package. This capsule is formulated for oral use and contains berotralstat hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Biocryst Pharmaceuticals, Inc. on December 04, 2020. The current certification is valid through December 31, 2027.
How is this Biocryst Pharmaceuticals, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 72769010101. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 4 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.